NRX Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
1201 ORANGE STREET, WILMINGTON, DE, 19801
Mailing Address
1201 ORANGE STREET, WILMINGTON, DE, 19801
Phone
484-254-6134
Fiscal Year End
1231
EIN
822844431
Financial Overview
FY2025
$12.96M
Total Assets
$28.89M
Total Liabilities
-$11.73M
Stockholders' Equity
$7.80M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 24, 2026 | View on SEC |
| 10-K Annual financial report | March 23, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | February 23, 2026 | View on SEC |
| 8-K Current report of material events | February 17, 2026 | View on SEC |
| 8-K Current report of material events | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 424B5 Prospectus supplement | February 17, 2026 | View on SEC |
| 3 Initial insider ownership report | February 17, 2026 | View on SEC |
| 8-K Current report of material events | February 2, 2026 | View on SEC |
| 8-K Current report of material events | January 16, 2026 | View on SEC |
Annual Reports
10-K
March 23, 2026
- Signed a significant licensing deal with Alvogen in June 2024, providing upfront payments, milestone payments, and future royalties without issuing new shares.
- Maintained an ongoing license deal with Sarah Herzog Memorial Hospital (since April 2021) with potential for milestone payments upon clinical trial completion and sales targets.
Material Events
8-K
Legal Issue
January 16, 2026
High Impact
- No immediate impact on the trading of NRX Pharmaceuticals' common stock (NRXP) or warrants (NRXPW).
- The company has proactively scheduled its 2025 Annual Meeting for March 23, 2026.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.